Company news

HeartSciences Inc. news in 2023

HeartSciences Inc.'s news releases, calls and decks from 2023, newest first.

View company

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

December 13, 2023

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

December 4, 2023

HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

November 19, 2023

HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

November 12, 2023

HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio

September 25, 2023

HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms

September 20, 2023

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

September 13, 2023

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

September 6, 2023

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

August 30, 2023

HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

August 23, 2023

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

August 16, 2023

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

July 18, 2023

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

May 8, 2023

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results

March 15, 2023

HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease

February 5, 2023

HeartSciences Announces Further Internationalization of its Patent Portfolio

February 2, 2023

HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive

January 3, 2023